Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Net Income (2016 - 2025)

Historic Net Income for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $9.0 million.

  • Coherus Oncology's Net Income fell 7561.33% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 21772.8%. This contributed to the annual value of $28.5 million for FY2024, which is 11198.32% up from last year.
  • Latest data reveals that Coherus Oncology reported Net Income of $9.0 million as of Q3 2025, which was down 7561.33% from $342.6 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Net Income high stood at $342.6 million for Q2 2025, and its period low was -$172.9 million during Q1 2021.
  • Its 5-year average for Net Income is -$1.4 million, with a median of -$39.6 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 58618.86% in 2021, then soared by 71714.52% in 2025.
  • Coherus Oncology's Net Income (Quarter) stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then tumbled by 95.46% to $9.0 million in 2025.
  • Its Net Income was $9.0 million in Q3 2025, compared to $342.6 million in Q2 2025 and -$9.2 million in Q1 2025.